|
| Study (year) | Chemical composition | Source | Purity (%) | Quality control reported |
|
| Chai et al. (2018) [21] | Isopsoralen | Chengdu Ruisifen Biological Technology Co., Ltd., CHN | NG | Batch number: 20180122 |
| van Luijk et al. (2013) [22] | Isopsoralen | Shanghai Chunyou Biotechnology Co., Ltd., CHN | ≥98% | HPLC |
| Moher et al. (2009) [23] | Psoralen | Guangdong Jingxin Biological Technology Co., Ltd., CHN | 98% | Batch number: 1202133231 |
| Macleod et al. (2004) [24] | Psoralen | Xinjiang Qikang Harbowei Pharmaceutical Co., Ltd., CHN | ≥98% | Batch number: 20151027 |
| Guyatt et al. (2011) [25] | Psoralen | National Institute for Food and Drug Control | NG | HPLC |
| Balshem et al. (2011) [26] | Isopsoralen | Chengdu Ruisifen Biological Technology Co., Ltd., CHN | NG | Batch number: 20180122 |
| Wang et al. (2021) [27] | Bakuchiol | Tianjin Crescent Lake Technology Co. Ltd., CHN | ≥95% | HPLC |
| Heinrich et al. (2020) [14] | Psoralen | Shenzhen China Resources Sanjiu Pharmaceutical Co., Ltd., CHN | ≥98% | Batch number: 20120920 |
| Shang et al. (2021) [28] | Isopsoralen | National Institute for the Control of Pharmaceutical and Biological Products | ≥98% | Batch number: 110738-201509 |
| Chen and Tang (2021) [29] | Psoralen | Jiangsu Yongjian Pharmaceutical Co., Ltd., CHN | NG | NG |
| Zhou et al. (2020) [30] | Isopsoralen | Sigma-Aldrich Corporation, USA | ≥99% | HPLC |
| Liu et al. (2020) [31] | Psoralen | Henan Luoyang Orthopedic Hospital, CHN | ≥98% | HPLC |
| Wang et al. (2019) [32] | Bavachin | NG | NG | NG |
| Zhang et al. (2019) [33] | Psoralidin | School of Pharmacy of Central South University, CHN | ≥98% | HPLC |
| Liu et al. (2017) [34] | Psoralen | The Second People’s Hospital of Shanxi Province, CHN | NG | NG |
| Huang and Zhou (2017) [35] | Bakuchiol | Korea Research Institute of Chemical Technology | ≥98% | HPLC |
|
